No activation of human pregnane x receptor by hyperforin-related phloroglucinolss

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 3, 2014, Pages 393-400

  Kandel, Benjamin A ^a,b   Ekins, Sean ^c,d,e,f   Leuner, Kristina ^g   Thasler, Wolfgang E ^h   Harteneck, Christian ^b   Zanger, Ulrich M ^a,b  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Collaborations in Chemistry ^*  (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^f UNC Hamner Institute for Drug Safety Sciences   (United States)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A1; HYPERFORIN; MULTIDRUG RESISTANCE PROTEIN 1; PHLOROGLUCINOL DERIVATIVE; PREGNANE X RECEPTOR; RIFAMPICIN; SULFORAPHANE; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6;

ABCB1 GENE; ALAS1 GENE; ARTICLE; CELL STRAIN HEPG2; COMPUTER MODEL; CONTROLLED STUDY; CYP2B6 GENE; CYP2C9 GENE; CYP3A4 GENE; CYP3A5 GENE; DRUG ANTAGONISM; DRUG POTENCY; DRUG RECEPTOR BINDING; GENE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; REPORTER GENE; UGT1A1 GENE;

CYTOCHROME P-450 CYP3A; GENES, REPORTER; HEP G2 CELLS; HEPATOCYTES; HUMANS; LUCIFERASES; MOLECULAR DOCKING SIMULATION; PHLOROGLUCINOL; PROMOTER REGIONS, GENETIC; RECEPTORS, STEROID; TERPENES; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84896722844     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.209916     Document Type: Article

References (53)

1. Ahmed SM, Banner NR, and Dubrey SW (2001) Low cyclosporin-A level due to Saint-John's-Wort in heart transplant patients. J Heart Lung Transplant 20:795.
2. Bachmann K, Patel H, Batayneh Z, Slama J, White D, Posey J, Ekins S, Gold D, and Sambucetti L (2004) PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res 50:237-246.
3. Bauer B, Yang X, Hartz AMS, Olson ER, Zhao R, Kalvass JC, Pollack GM, and Miller DS (2006) In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 70: 1212-1219.
4. Biswas A, Mani S, Redinbo MR, Krasowski MD, Li H, and Ekins S (2009) Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res 26:1807-1815.
5. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, and Müller WE (1998) Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 63:499-510.
6. Chen Y, Ferguson SS, Negishi M, and Goldstein JA (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308:495-501.
7. Chrencik JE, Orans J, Moore LB, Xue Y, Peng L, Collins JL, Wisely GB, Lambert MH, Kliewer SA, and Redinbo MR (2005) Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol 19:1125-1134.
8. Ekins S and Erickson JA (2002) A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos 30:96-99.
9. Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, Iyer M, Kholodovych V, Ai N, Welsh WJ, and Sinz M, et al. (2007) Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol 72:592-603.
10. Ekins S, Honeycutt JD, and Metz JT (2010) Evolving molecules using multi-objective optimization: applying to ADME/Tox. Drug Discov Today 15:451-460.
11. Ekins S, Kholodovych V, Ai N, Sinz M, Gal J, Gera L, Welsh WJ, Bachmann K, and Mani S (2008a) Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol 74:662-672.
12. Ekins S, Kortagere S, Iyer M, Reschly EJ, Lill MA, Redinbo MR, and Krasowski MD (2009) Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLOS Comput Biol 5:e1000594.
13. Ekins S, Reschly EJ, Hagey LR, and Krasowski MD (2008b) Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol 8:103.
14. Erdelmeier C, Grethlein E, Lang F, Oschmann R, and Stumpf K-H (2001a) inventors, Dr. Willmar Schwabe GmbH & Co., assignee. Stable extract of Hypericum perforatum L., a method for producing the same, and corresponding pharmaceutical preparation. U.S. patent 6,241,988 B1. 2001 Jun 5.
15. Erdelmeier C, Grethlein E, Lang F, Oschmann R, and Stumpf K-H (2001b) inventors, Dr. Willmar Schwabe GmbH & Co., assignee. Stable extract of Hypericum perforatum L., process for preparing the same and pharmaceutical compositions. U.S. patent 6,280,736 B1. 2001 Aug 28.
16. Goodwin B, Moore LB, Stoltz CM, McKee DD, and Kliewer SA (2001) Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 60: 427-431.
17. Haslam IS, Jones K, Coleman T, and Simmons NL (2008) Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84). Biochem Pharmacol 76:850-861.
18. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann U, Eichelbaum M, and Wojnowski L, et al. (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29:1454-1459.
19. Ihunnah CA, Jiang M, and Xie W (2011) Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta 1812:956-963.
20. Istrate MA, Nussler AK, Eichelbaum M, and Burk O (2010) Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding. Biochem Biophys Res Commun 393:688-693.
21. Kasper S, Anghelescu I-G, Szegedi A, Dienel A, and Kieser M (2006) Superior efficacy of St John's Wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med 4:14.
22. Klemow KM, Bartlow A, Crawford J, Kocher N, Shah J, and Ritsick M (2011) Medical attributes of St. John's Wort (Hypericum perforatum), in Herbal Medicine: Biomolecular and Clinical Aspects (Benzie IFF and Wachtel-Galor S, eds) pp 211-239, CRC Press, Boca Raton, FL.
23. Kliewer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687-702.
24. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CYW, and Cui YY, et al. (2004) Induction and inhibition of cytochromes P450 by the St. John's Wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32:512-518.
25. Kortagere S, Chekmarev D, WelshWJ, and Ekins S (2009) Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res 26:1001-1011.
26. Kortagere S, Krasowski MD, and Ekins S (2012) Ligand-and structure-based pregnane X receptor models. Methods Mol Biol 929:359-375.
27. Laakmann G, Schüle C, Baghai T, and Kieser M (1998) St. John's Wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31 (Suppl 1):54-59.
28. Leuner K, Heiser JH, Derksen S, Mladenov MI, Fehske CJ, Schubert R, Gollasch M, Schneider G, Harteneck C, and Chatterjee SS, et al. (2010) Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators-identification of a novel pharmacophore. Mol Pharmacol 77:368-377.
29. Leuner K, Kazanski V, Müller M, Essin K, Henke B, Gollasch M, Harteneck C, and Müller WE (2007) Hyperforin-a key constituent of St. John's Wort specifically activates TRPC6 channels. FASEB J 21:4101-4111.
30. Li H, Redinbo MR, Venkatesh M, Ekins S, Chaudhry A, Bloch N, Negassa A, Mukherjee P, Kalpana G, and Mani S (2013) Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem 288:13655-13668.
31. Linde K, Berner MM, and Kriston L (2008) St John's Wort for major depression. Cochrane Database Syst Rev (4):CD000448.
32. Madabushi R, Frank B, Drewelow B, Derendorf H, and Butterweck V (2006) Hyperforin in St. John's Wort drug interactions. Eur J Clin Pharmacol 62:225-233.
33. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, and Kliewer SA (2000) St. John's Wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500-7502.
34. Müller WE (2003) Current St John's Wort research from mode of action to clinical efficacy. Pharmacol Res 47:101-109.
35. Müller WE, Singer A, Wonnemann M, Hafner U, Rolli M, and Schäfer C (1998) Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 31 (Suppl 1):16-21.
36. Noble SM, Carnahan VE, Moore LB, Luntz T, Wang H, Ittoop OR, Stimmel JB, Davis-Searles PR, Watkins RE, and Wisely GB, et al. (2006) Human PXR forms a tryptophan zipper-mediated homodimer. Biochemistry 45:8579-8589.
37. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, and Falloon J (2000) Indinavir concentrations and St John's Wort. Lancet 355:547-548.
38. Rao SN, Head MS, Kulkarni A, and LaLonde JM (2007) Validation studies of the sitedirected docking program LibDock. J Chem Inf Model 47:2159-2171.
39. Spurgeon SL, Jones RC, and Ramakrishnan R (2008) High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS ONE 3:e1662.
40. Teotico DG, Bischof JJ, Peng L, Kliewer SA, and Redinbo MR (2008) Structural basis of human pregnane X receptor activation by the hops constituent colupulone. Mol Pharmacol 74:1512-1520.
41. Thomas M, Burk O, Klumpp B, Kandel BA, Damm G, Weiss TS, Klein K, Schwab M, and Zanger UM (2013) Direct transcriptional regulation of human hepatic cytochrome P450 3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARa). Mol Pharmacol 83:709-718.
42. Treiber K, Singer A, Henke B, and Müller WE (2005) Hyperforin activates nonselective cation channels (NSCCs). Br J Pharmacol 145:75-83.
43. Vlachojannis J, Cameron M, and Chrubasik S (2011) Drug interactions with St. John's Wort products. Pharmacol Res 63:254-256, author reply 257-258.
44. Watkins RE, Davis-Searles PR, Lambert MH, and Redinbo MR (2003a) Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331:815-828.
45. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searles PR, Lambert MH, Kliewer SA, and Redinbo MR (2003b) 2.1 A crystal structure of human PXR in complex with the St. John's Wort compound hyperforin. Biochemistry 42:1430-1438.
46. Watkins RE, Noble SM, and Redinbo MR (2002) Structural insights into the promiscuity and function of the human pregnane X receptor. Curr Opin Drug Discov Devel 5:150-158.
47. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, and Redinbo MR (2001) The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292: 2329-2333.
48. Williams AJ, Ekins S, Spjuth O, and Willighagen EL (2012) Accessing, using, and creating chemical property databases for computational toxicology modeling. Methods Mol Biol 929:221-241.
49. Xue Y, Chao E, Zuercher WJ, Willson TM, Collins JL, and Redinbo MR (2007a) Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem 15:2156-2166.
50. Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, and Redinbo MR (2007b) Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol 21:1028-1038.
51. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, and Bachmann K (2008) A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos 36:1689-1697.
52. Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103-141.
53. Zhang B, Xie W, and Krasowski MD (2008) PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9:1695-1709.